Despite its size and novel design, the STRESS trial could not deliver an answer to the clinical conundrum of whether perioperative steroids are warranted.
Two studies report few complications from continuing ocrelizumab and natalizumab into pregnancy, with high live birth rates, a decline in elective abortions, and few major congenital abnormalities in newborns.